AbbVie licensed ISB 2001, a novel trispecific T-cell engager targeting BCMA, CD38, and CD3, from Ichnos Glenmark Innovation for potentially over $1.9 billion. In a Phase I trial reported at ASCO 2025, ISB 2001 displayed a 79% overall response rate and 30% stringent complete response in heavily pretreated relapsed/refractory multiple myeloma patients with a favorable safety profile. The drug employs IGI’s BEAT® protein platform for enhanced avidity and safety. Experts view multispecific antibodies as a new frontier in immuno-oncology, with ISB 2001 poised to redefine treatment options for this patient population.